We are live on
!
Find out more
SC
Sophrosyne Capital Portfolio holdings
AUM
$11.5M
1-Year Est. Return
17.82%
This Fund
S&P 500
This Quarter
Est. Return
+4.25%
1 Year Est. Return
+17.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$13.4M
AUM Growth
-$44.9M
(-77%)
Cap. Flow
-$45.1M
Cap. Flow
% of AUM
-337.36%
Top 10 Holdings %
Top 10 Hldgs %
98.59%
Holding
35
New
1
Increased
–
Reduced
13
Closed
20
Avg Time Held
4.5
quarters
Top 10 Avg Time Held
3
quarters
Top 20 Avg Time Held
2.7
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GMO
General Moly, Inc.
GMO
|
+$11.4K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iRadimed
IRMD
|
+$4.94M |
| 2 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
+$4.51M |
| 3 |
Strategy Inc
MSTR
|
+$4.16M |
| 4 |
BioTelemetry, Inc.
BEAT
|
+$3.65M |
| 5 |
PKT
PROCERA NETWORKS INC NEW COM STK (DE)
PKT
|
+$2.13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.11% |
| 2 | Utilities | 22.83% |
| 3 | Communication Services | 8.27% |
| 4 | Financials | 7.81% |
| 5 | Industrials | 7.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
BioTelemetry, Inc.
BEAT
| $4.08M | 30.55% |
432,853
-394,451
| -48% | -$3.65M |
2013 Q2
8 quarters
|
|
2
Pure Cycle
PCYO
$269M
| $3.05M | 22.83% |
587,026
-44,300
| -7% | -$230K |
2013 Q2
8 quarters
|
|
|
3
iRadimed
IRMD
$1.14B
| $1.6M | 11.98% |
68,751
-270,407
| -80% | -$4.94M |
2014 Q3
3 quarters
|
|
|
MEET
4
DELISTED
The Meet Group, Inc. Common Stock
MEET
| $1.1M | 8.27% |
650,000
-854,032
| -57% | -$1.4M |
2013 Q2
8 quarters
|
|
|
BFYT
5
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
| $1.04M | 7.81% |
209,925
-272,995
| -57% | -$1.72M |
2014 Q1
5 quarters
|
|
6
Cadiz
CDZI
$282M
| $878K | 6.57% |
101,189
-137,667
| -58% | -$1.2M |
2013 Q3
7 quarters
|
|
7
Axogen
AXGN
$2.14B
| $745K | 5.58% |
237,266
-252,463
| -52% | -$815K |
2013 Q3
7 quarters
|
|
|
ENVI
8
DELISTED
ENVIVIO INC COM STK (DE)
ENVI
| $446K | 3.34% |
234,852
-290,722
| -55% | -$523K |
2013 Q2
8 quarters
|
|
9
AeroVironment
AVAV
$6.34B
| $156K | 1.17% |
6,000
-42,300
| -88% | -$1.12M |
2013 Q3
7 quarters
|
|
10
Limoneira
LMNR
$220M
| $67K | 0.5% |
3,000
-3,200
| -52% | -$71.7K |
2015 Q1
1 quarter
|
|
11
Balchem Corp
BCPC
$5.38B
| $61K | 0.46% |
1,100
-16,400
| -94% | -$944K |
2014 Q3
3 quarters
|
|
|
OPWR
12
DELISTED
OPOWER INC COM STK (DE)
OPWR
| $45K | 0.34% |
3,900
| – | – |
2015 Q1
1 quarter
|
|
13
Darling Ingredients
DAR
$9.81B
| $40K | 0.3% |
2,700
-18,500
| -87% | -$273K |
2015 Q1
1 quarter
|
|
14
DELISTED
Calavo Growers
CVGW
| $31K | 0.23% |
600
-250
| -29% | -$13K |
2015 Q1
1 quarter
|
|
|
GMO
15
DELISTED
General Moly, Inc.
GMO
| $11K | 0.08% |
+16,000
| New | +$11.4K |
2015 Q2
0 quarters
|
|
|
16
Strategy Inc
MSTR
$61.8B
| – | – |
-246,000
| Closed | -$4.16M | – |
|
17
DELISTED
S&W Seed Co
SANW
| – | – |
-4,505
| Closed | -$395K | – |
|
18
Silicom
SILC
$297M
| – | – |
-43,200
| Closed | -$1.78M | – |
|
19
Smith Micro Software
SMSI
$13.9M
| – | – |
-2,653
| Closed | -$543K | – |
|
20
Tempest Therapeutics
TPST
$11.2M
| – | – |
-3
| Closed | -$323K | – |
|
21
Ubiquiti
UI
$36.8B
| – | – |
-60,000
| Closed | -$1.77M | – |
|
|
CSII
22
DELISTED
Cardiovascular Systems, Inc.
CSII
| – | – |
-48,400
| Closed | -$1.89M | – |
|
|
IPHI
23
DELISTED
INPHI CORPORATION
IPHI
| – | – |
-68,300
| Closed | -$1.21M | – |
|
|
ENT
24
DELISTED
Global Eagle Entertainment Inc.
ENT
| – | – |
-3,896
| Closed | -$1.29M | – |
|
25
DELISTED
Calgon Carbon Corp
CCC
| – | – |
-13,700
| Closed | -$289K | – |
|
Similar funds
SFM
IACGFA
LS
NGPI
AP
GRP
NVPV
AC
Sophrosyne Capital's Q2 2015 Portfolio in Review
As of Q2 2015, Sophrosyne Capital held 35 positions worth $13.4M, down 77% from $58.3M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Sophrosyne Capital withdrew a net $45.1M in Q2 2015, closing 20 positions and reducing 13 holdings. Its most notable exit was ZELTIQ Aesthetics, Inc., an estimated $4.51M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 37% a quarter earlier, followed by Utilities and Communication Services.
Against the trend, Sophrosyne Capital opened a new position in General Moly, Inc. worth $11K.
- Sophrosyne Capital's largest Q2 2015 buy was General Moly, Inc.: 16,000 shares worth $11K.
- Sophrosyne Capital's biggest Q2 2015 reduction was iRadimed, cutting an estimated $4.94M.
- Sophrosyne Capital fully exited ZELTIQ Aesthetics, Inc. in Q2 2015, selling an estimated $4.51M.
- Sophrosyne Capital's ten largest holdings make up 99% of its $13.4M portfolio in Q2 2015.
- Sophrosyne Capital opened 1 new position and closed 20 in Q2 2015.
- Sophrosyne Capital's portfolio value fell 77% quarter-over-quarter to $13.4M.
Based on Sophrosyne Capital's 13F filing for Q2 2015, filed 14 Aug 2015.